Exploring Derivatives of Quinolizidine Alkaloid Sophoridine in the Design and Biological Mechanistic Evaluation of Histone Deacetylase Inhibitors against Triple-Negative Breast Cancer

Anti-proliferative and photodynamic activities of Senna didymobotrya (Fresen.) leaf alkaloid-rich extracts against breast cancer cells

BACKGROUND

Amongst all neoplastic diseases, breast cancer represents a major cause of death among the female population in developed and developing countries. Since alkaloid drugs are commonly used in chemotherapy to manage this disease, this study investigated the anti-proliferative effectiveness of alkaloid-rich fractions of Senna didymobotrya leaves only and with laser irradiation against MCF-7 breast cancer cells.

METHOD AND MATERIALS

A powdered sample of the plant leaves was extracted with 50% ethanol, filtered and their pH was adjusted with acid and base solution followed by partitioning with chloroform and ethyl acetate solvents. Cells were treated with 240 μg/mL of the respective extracts, while those in the photodynamic therapy groups, cells were exposed to laser (405 nm wavelength and 10 Jcm-2) irradiation 6 h post extracts' administration.

RESULTS

Treatment with the S. didymobotrya leaves alkaloid extracts significantly decreased the ATP concentration and overall viability of the MCF-7 cells. Reactive oxygen species (ROS) levels in cell groups treated with the extracts and laser light were considerably higher than in experimental groups treated with only the extracts. Moreover, the molecular docking analysis revealed the involvement of only hydrophobic bonds in the interactions of the plant's alkaloid-derived phytoconstituents' with selected cancer protein biomarkers.

CONCLUSION

Although the in silico analysis suggests that the plant-identified alkaloid phytoconstituents inhibition of estrogen receptor-alpha, human epidermal growth factor receptor-2 and progesterone receptor proteins involved in breast cancer pathogenesis could explain a possible mechanism for the observed anticancer effect, more detailed in vitro molecular experiments are necessary to confirm these findings.

Emerging therapeutic strategies in cancer therapy by HDAC inhibition as the chemotherapeutic potent and epigenetic regulator

In developing new cancer medications, attention has been focused on novel epigenetic medicines called histone deacetylase (HDAC) inhibitors. Our understanding of cancer behavior is being advanced by research on epigenetics, which also supplies new targets for improving the effectiveness of cancer therapy. Most recently published patents emphasize HDAC selective drugs and multitarget HDAC inhibitors. Though significant progress has been made in emerging HDAC selective antagonists, it is urgently necessary to find new HDAC blockers with novel zinc-binding analogues to avoid the undesirable pharmacological characteristics of hydroxamic acid. HDAC antagonists have lately been explored as a novel approach to treating various diseases, including cancer. The complicated terrain of HDAC inhibitor development is summarized in this article, starting with a discussion of the many HDAC isotypes and their involvement in cancer biology, followed by a discussion of the mechanisms of action of HDAC inhibitors, their current level of development, effect of miRNA, and their combination with immunotherapeutic.